AbCellera Biologics Inc.
ABCL Healthcare Biotechnology
AbCellera Biologics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $75.1 million, up 160.6% from fiscal 2024. In the quarter to June 2026, revenue fell 76.3%, EPS fell 50.0% and free cash flow grew 152.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow ABCL
AbCellera Biologics Inc. (ABCL) EV/Sales
As of 16 October 2026, AbCellera Biologics Inc. (ABCL) trades at a EV/Sales of 46.0×. Over the past ten years it has ranged from −2.3× (April 2025) to 59.9× (September 2026); the current reading is higher than 98% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 6.2× | (16.86%) |
| FY2024 | 7.5× | (67.56%) |
| FY2023 | 23.0× | 521.40% |
| FY2022 | 3.7× | (56.58%) |
| FY2021 | 8.5× | (65.82%) |
| FY2020 | 24.9× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 27.8× | 313.74% |
| Mar 2026 | 6.7× | 8.13% |
| Dec 2025 | 6.2× | (77.77%) |
| Sep 2025 | 27.9× | 104.29% |
| 22 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| TLX Telix Pharmaceuticals Limited compare | n/m |
| EWTX Edgewise Therapeutics, Inc. compare | n/m |
| DFTX Definium Therapeutics, Inc. compare | n/m |
| LEGN Legend Biotech Corporation Sponsored ADR compare | 2.2× |
| ARQT Arcutis Biotherapeutics, Inc. compare | 7.8× |
| TNGX Tango Therapeutics, Inc. compare | 36.7× |
| ABCL AbCellera Biologics Inc. | 46.0× |
| RLAY Relay Therapeutics, Inc. compare | 217× |
| DNTH Dianthus Therapeutics, Inc. compare | 1,656× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)